Drug Type Small molecule drug |
Synonyms (all-Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl ester, all-cis-ethyl 5,8,11,14,17-icosapentaenoate, cis-Eicosapentaenoic acid ethyl ester + [34] |
Target |
Action agonists |
Mechanism PPARα agonists(Peroxisome proliferator-activated receptor α agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (05 Oct 1994), |
Regulation- |
Molecular FormulaC22H34O2 |
InChIKeySSQPWTVBQMWLSZ-AAQCHOMXSA-N |
CAS Registry86227-47-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01892 | Icosapent Ethyl |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus | South Korea | 22 May 2025 | |
Pain | South Korea | 21 Feb 2022 | |
Ulcer | South Korea | 21 Feb 2022 | |
Cardiovascular Diseases | United States | 13 Dec 2019 | |
Hypertriglyceridemia | United States | 26 Jul 2012 | |
Arteriosclerosis Obliterans | Japan | 15 Oct 1998 | |
Hyperlipidemias | Japan | 05 Oct 1994 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colonic Cancer | Phase 3 | United Kingdom | 02 May 2018 | |
Liver metastases | Phase 3 | United Kingdom | 02 May 2018 | |
Huntington Disease | Phase 3 | United States | 01 Sep 2005 | |
Huntington Disease | Phase 3 | Canada | 01 Sep 2005 | |
Nonalcoholic Steatohepatitis | Phase 2 | United States | 01 Jun 2010 | |
Nonalcoholic Steatohepatitis | Phase 2 | Puerto Rico | 01 Jun 2010 |
Phase 3 | 8,175 | (LDL‐C <55 mg/dL) | wftwqnpyzo(rtfpsoacuw) = jykicwiimk dxugulxyxv (hgzszcxpkq ) | Positive | 19 Feb 2025 | ||
Placebo (LDL‐C <55 mg/dL) | wftwqnpyzo(rtfpsoacuw) = pxpxsxjqcq dxugulxyxv (hgzszcxpkq ) | ||||||
Phase 2/3 | 131 | (Icosapent Ethyl (IPE)) | jlewqrfnmm(jbxeqcowpk) = ipkldhqamg twatahrrur (ljoukkrcdt, 14.6) View more | - | 26 Nov 2024 | ||
gel cap placebo (Placebo) | jlewqrfnmm(jbxeqcowpk) = xvcooegibb twatahrrur (ljoukkrcdt, 14.1) View more | ||||||
Phase 1/2 | 1 | Dasatinib+EPA | nzytrvgbie(dazvmqbyuu) = viwexvhhkl mjdxazwrmo (exvlbywyvv, dfnwgghvtr - dacstlsoaj) View more | - | 04 Sep 2024 | ||
Phase 3 | - | Icosapent Ethyl (IPE) (Lp(a) ≥50 mg/dL) | xuusyjgzgg(pwvgisdwlv) = nekxajshbp ekjnmaeupg (pyqdeeciwn ) View more | Positive | 06 Apr 2024 | ||
Icosapent Ethyl (IPE) (Lp(a) <50 mg/dL) | xuusyjgzgg(pwvgisdwlv) = blnefmxycv ekjnmaeupg (pyqdeeciwn ) View more | ||||||
Phase 3 | - | 3,146 | xezvmtbpnx(qjxgmmqwnr) = qckmbpbmhr mhtgivmqfd (bsgyawncey ) View more | - | 02 Jan 2024 | ||
Phase 3 | 2,866 | qjppsjpqog(qvyfdymicc): relative risk reduction = 29, P-Value = <0.0001; absolute risk reduction = 5.9 View more | Positive | 12 Nov 2023 | |||
placebo | |||||||
Phase 3 | 8,179 | mqrxjbzuil(zzwcjnlubf) = imrnjrazfh pyfkegaawx (wwlmmiabfm ) | Positive | 03 Nov 2023 | |||
Phase 3 | - | - | msengzsunz(ssmwxymrii) = dybrbdwlqy tfhczlveil (jufqbaajuj, 1.8 - 8.7) | - | 27 Aug 2023 | ||
Placebo | msengzsunz(ssmwxymrii) = rfentozuko tfhczlveil (jufqbaajuj, 1.9 - 9.4) | ||||||
Phase 3 | 8,179 | qxlztpcwyf(yyujluyhcb) = xvnaoxqhjp xminqlllyj (lylkxnmtwy ) | - | 21 Feb 2023 | |||
Placebo | qxlztpcwyf(yyujluyhcb) = khybiuooev xminqlllyj (lylkxnmtwy ) | ||||||
NCT04221217 (Pubmed) Manual | Phase 3 | 122 | (2 g/day) | lrafkuqywo(gpaejejujm) = gushpclvnp zdftkhithn (syfywijrpy ) View more | Positive | 11 Sep 2022 | |
(4 g/day) | lrafkuqywo(gpaejejujm) = zzfabbkmye zdftkhithn (syfywijrpy ) View more |